

THE *Beljanski* FOUNDATION

NEWSLETTER

The *Beljanski* Foundation



Monique Beljanski

President of the Beljanski Foundation

over which I have the honor of presiding, serves the interests of anyone seeking to understand the thought process of a thoroughly non-conformist and pioneering mind. The various health applications that have made the Beljanski name well known in Europe are merely the most recent aspects to emerge from a body of research of rare richness which, today, still remains very much on the cutting edge. Nowhere is this more apparent than with the current fervor over influence of RNA on genetic behavior. This was precisely the subject matter researched by Mirko Beljanski since the late sixties, and it is this research, too advanced for most to understand at the time, which made it possible to develop RNA-fragments able to restore bone marrow stem cells, and, thus, immunity, so often battered by classical treatments. The same situation exists with the notion of selective targeting of unhealthy cells, again cited these days as an avant-garde researcher's dream, though confirmed daily by the positive results seen in so many patients!

The Beljanski Foundation was vested with the mission of furthering research and educating the public. It also works to preserve the rare plants whose extracts are being used in the research being sponsored by The Foundation. Yet, above all, it remains committed to the mission of preserving the scientific concepts -- still largely unexploited -- left to us by Mirko Beljanski. The development of these still unexploited pathways reflects a wealth of possibilities for tomorrow's health.

Making this work a reality can only be done independent of the business community. That is why the Foundation was created. And through your support, we will continue to move forward.

- M. Beljanski



Monique and Mirko Beljanski
in their laboratory in France
c. 1994

THE CENTER OF HOLISTIC UROLOGY AT COLUMBIA UNIVERSITY CONFIRMS DR. BELJANSKI'S RESEARCH AND TAKES IT ONE STEP FURTHER

Pao pereira and Rauwolfia vomitoria are two plants which have been extensively studied, both in vitro and in vivo, by Dr. Mirko Beljanski for their ability to selectively target the destabilized DNA of cancerous cells and prevent DNA's replication of these cells.

On July 12th a reception was hosted at the Cornell Club in Manhattan to announce the beginning of a clinical trial on an innovative and all natural blend of Pao Pereira and Rauwlofia vomitoria. Strong preclinical data concerning the extracts have been generated during two years of intensive studies conducted by the Center of Holistic Urology at Columbia University, whose Director, Dr. Aaron Katz, was the recipient of the 2005 Beljanski Foundation Award.

(continued from previous page)

Debra Bemis, PhD, who was in charge of the research at Columbia University, described the experiments she conducted and concluded that they demonstrated the promising anti-cancer activity of the Pao pereira and Rauwolfia vomitoria extracts. In these studies, mice were injected with human prostate cancer cells. Dr. Bemis found that both the Pao and the Rauwolfia extracts significantly reduced the volume of tumors in these animals and also demonstrated that the extracts killed prostate cancer cells while having no ill effects on the normal cells of the mice. Further studies showed that the two extracts exert their effect by different mechanisms. She concluded by saying that the combination of the two extracts would take advantage of both mechanisms and thus provide a basis for synergistic anti-cancer activity.

For more information regarding the research, please contact: info@beljanskifoundation.com



Debra Bemis, PhD, introducing pre-clinical research she conducted at Columbia University

DR. KATZ ANNOUNCES THAT COLUMBIA UNIVERSITY IS READY TO LAUNCH A CLINICAL TRIAL WITH PROSTABEL®



Dr. Aaron Katz, speaking at the Cornell Club about his upcoming clinical trial

Dr. Katz opened his remarks by reiterating the commitment of Columbia University's Center for Holistic Urology to bringing you the best and latest information on holistic therapies and preventative medicine. He then went on to describe the clinical trial he is now conducting on Pao pereira and Rauwolfia vomitoria extracts, explaining that it is designed for men with an elevated PSA (marker for prostate cancer) but with a negative biopsy. He indicated that at present there are no products available that treat the symptoms and help prevent the onset of prostate cancer. Citing the strong preclinical data generated by two years of intensive studies conducted by the Columbia University research team, Dr. Katz voiced the hope that the participants in this study would respond favorably to the product. He concluded by saying evaluation of natural products as a means to maintaining prostate health is a primary goal of the Center of Holistic Urology at Columbia University.

For more information on the clinical trial and the Center of Holistic Urology, please refer to: www.holisticurology.com

CANCER TREATMENT CENTERS OF AMERICA ALSO BECOME INVOLVED WITH THE DISCOVERIES OF MIRKO BELJANSKI

John Hall, PhD, Director of Research at Natural Source International Ltd, brought everyone up to date on the preliminary results of a separate clinical trial that is already underway at the Cancer Treatment Centers of America (CTCA). This trial was designed to assess the potential of ReaLBuild®, a ribonucleic acid extract (also stemming from the research Dr. Beljanski conducted on RNA) in enhancing white blood cell generation. Critical loss of white blood cells and impaired immunity due to the cytotoxic effects of chemotherapy are known to pose a major risk to the survival of these patients. In their interim report, the investigators at CTCA noted that a significant increase in the white blood cell counts of most patients enabled them to complete their treatment without interruption. The investigators referred to these preliminary results as "spectacular."

For more information regarding the research, please contact: info@beljanskifoundation.com



John Hall, PhD, discussing work with Cancer Treatment Centers of America

RESEARCH AND DEVELOPMENT FOR THE CURES OF TOMORROW: HOW YOU CAN HELP

Are you tired of contributing to medical research without ever seeing a result?

The *Beljanski* Foundation, like other, similar organizations, is committed to funding cutting-edge medical research and looks to the public to help fund tomorrow's cures. Your tax-deductible donation to The Beljanski Foundation does not disappear into a blackhole, leaving the donor to wonder in what ways their contribution was applied. Rather, donors are kept up-to-date with a bi-annual newsletter from The Foundation. The newsletter provides a progress report which details preliminary and final results, as they become available, from the specific research projects that donors' funds have gone to support. The *Beljanski* Foundation thereby allows donors to have a window into the world of research.

The Beljanski Foundation Inc is a 501(c)(3) non-profit organization. Contributions are tax deductible to the extent allowed by law.

Tax ID:13-4086570

The BELJANSKI FOUNDATION, INC

217 E. 86thSt., PMB #101, New York, NY 10028

Web: www.beljanskifoundation.com. Email: info@beljanskifoundation.com